Business Context and Reporting Period
X4 Pharmaceuticals, Inc. (XFOR) filed a Form 8-K Current Report on August 22, 2025. The filing addresses corporate governance changes involving the Board of Directors.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting personnel changes.
Material Changes
- Board Resignations: David McGirr and R. Keith Woods resigned from the Board of Directors and all associated committees effective immediately on August 22, 2025.
- Reason for Departure: The resignations were not the result of any disagreement with the Company regarding operations, policies, or practices.
- Committee Appointments: Michael Wyzga was appointed Chair of the Audit Committee. Francoise de Craecker and Gary Bridger were appointed as members of the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the immediate personnel changes.
Key Facts for Investor Verification
- Confirm the new composition of the Audit Committee (Chair: Michael Wyzga; Members: Francoise de Craecker, Gary Bridger).
- Verify the total number of remaining directors on the Board following the resignations of McGirr and Woods.
- Check for any subsequent filings regarding the appointment of new directors to fill the vacancies left by the resignations.